Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

NCT ID: NCT04585490

Last Updated: 2025-05-06

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-25
• Study Completion Date: 2028-04-01

Brief Summary

The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

Detailed Description

Primary objective is to measure the change in the levels of circulating tumor DNA (ctDNA) in Cohort 1 (MRD+) due to the addition of Tremelimumab and platinum doublet chemotherapy in subjects with stage III unresectable disease with positive DNA treated with consolidation chemotherapy and immunotherapy.

Secondary Objectives:

To determine the proportion of subjects in Cohort 1 MRD+ for whom ctDNA becomes undetectable after adding chemotherapy and tremelimumab to consolidation durvalumab

To describe compare overall survival (OS) of subjects with baseline detectable ctDNA (Cohort 1 MRD+) vs baseline undetectable ctDNA (Cohort 2 MRD ) ·To compare progression free survival (PFS) between subjects with baseline detectable (Cohort 1 MRD+) vs baseline undetectable ctDNA (Cohort 2 MRD )

Conditions

Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1 minimal residual disease positive (MRD+)

Subjects with detectable ctDNA will receive 4 cycles of platinum doublet chemotherapy \[carboplatin/pemetrexed\], tremelimumab (75 mg IV every 21 days) and durvalumab (1500 mg IV every 21 days), except subjects with squamous cell carcinoma histology will receive carboplatin/paclitaxel. Subjects will be evaluated with PET/CT and/or computed tomography (CT) thorax every 12 weeks. Following ctDNA evaluation, in the absence of progression or toxicity, subject will continue with durvalumab to complete 1 year of treatment as standard of care.

Group Type: EXPERIMENTAL

Durvalumab

Intervention Type: DRUG

Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)

Carboplatin

Intervention Type: DRUG

Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle

Pemetrexed

Intervention Type: DRUG

500mg/m2 on Day 1 of every 21-day cycle

Paclitaxel

Intervention Type: DRUG

175mg/m2 on Day 1 of every 21-day cycle

Cisplatin

Intervention Type: DRUG

Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin

AVENIO ctDNA Surveillance Kit

Intervention Type: DEVICE

Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

Tremelimumab

Intervention Type: DRUG

not to exceed 75mg IV on Day 1 of every 21-day cycle

Cohort 2 minimal residual disease negative (MRD )

Subjects with undetectable ctDNA at study enrollment will receive standard of care durvalumab (10 mg/kg every 2 weeks, or equivalent, for 1 year). If subjects in Cohort 2 MRD progress prior to close of study, blood will be drawn for ctDNA testing.

Group Type: EXPERIMENTAL

Durvalumab

Intervention Type: DRUG

Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)

AVENIO ctDNA Surveillance Kit

Intervention Type: DEVICE

Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

Interventions

Durvalumab

Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)

Intervention Type: DRUG

Carboplatin

Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle

Intervention Type: DRUG

Pemetrexed

500mg/m2 on Day 1 of every 21-day cycle

Intervention Type: DRUG

Paclitaxel

175mg/m2 on Day 1 of every 21-day cycle

Intervention Type: DRUG

Cisplatin

Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin

Intervention Type: DRUG

AVENIO ctDNA Surveillance Kit

Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)

Intervention Type: DEVICE

Tremelimumab

not to exceed 75mg IV on Day 1 of every 21-day cycle

Intervention Type: DRUG

Other Intervention Names

Imfinzi; MEDI-4736; MEDI4736; Carboplat; Carbosol; Carboplatino; cis-diammine(cyclobutane-1,1-dicarboxylato)platinum; Alimta; MTA; LY231514; L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl); Praxel; platinum diamminodichloride; Abiplatin; Cismaplat; cis-platinum; Platinex; platinum, diaminedichloro-, cis- (8CI); Imjudo; Tremelimumab-actl; Ticilimumab; CP-675; CP-675,206

Eligibility Criteria

Inclusion Criteria

1. Histologically- or cytologically-documented NSCLC presenting with locally-advanced, unresectable stage III disease (Version 8 of AJCC Staging Manual) or NSCLC with locoregional recurrence after previous definitive treatment.

2. For stage III or recurrent disease, must have completed platinum-based chemotherapy and radiation therapy to all known tumor sites (60 Gy +/- 10%). Must not have known progression of disease.

3. Must be receiving consolidation durvalumab following completion of radiation and chemotherapy, and less than 32 weeks has elapsed from their first dose of durvalumab. (Patients may sign consent for study before start of durvalumab, but confirm eligibility and enroll only after first dose of durvalumab is received).

4. Able to potentially receive further consolidation chemotherapy plus durvalumab and tremelimumab, but not be currently intended to receive additional systemic consolidation chemotherapy apart from this durvalumab.

5. Pre-treatment tumor tissue or tumor DNA sample is believed to be available for analysis

6. Aged 18 years or older

7. Weight > 30kg

8. Life expectancy ≥ 12 weeks

9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

10. Absolute neutrophil count > 1.0 x 109/L (1000/mm3)

11. Platelets > 75 x 109/L (100,000/mm3)

12. Hemoglobin ≥ 9.0 g/dL (5.59 mmol/L)

13. Measured creatinine clearance > 40 mL/min, by either 24 hour urine collection or the Cockcroft Gault formula

Males:

Mass(kg) x (140-Age) / 72 x serum creatinine (mg/dL)

Females:

Mass(kg) x (140-Age) x 0.85 / 72 x serum creatinine (mg/dL)

14. Serum bilirubin ≤ 1.5 x upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology) who will be allowed in consultation with their physician.

15. aspartate aminotransferase (AST) (SGOT)/Alanine Aminotransferase (ALT) (SGPT) ≤ 2.5 x institutional upper limit of normal (ULN) unless liver metastases are present, in which case it must be ≤ 5 x ULN

16. Ability to understand and the willingness to sign the written IRB approved informed consent document.

• Subjects with Grade ≥ 2 neuropathy will be evaluated on a case by case basis after consultation with the Protocol Director / Principal Investigator
• Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by treatment with durvalumab may be included (ie, hearing loss) only after consultation with the Protocol Director / Principal Investigator.

8. Any prior Grade ≥ 3 immune related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > Grade 1) that may limit subject from continuing durvalumab during the study

9. Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug.

10. Active or prior documented autoimmune or inflammatory disorders which is likely to limit the subjects ability to continue durvalumab on the study (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis; Graves' disease; rheumatoid arthritis; hypophysitis; uveitis; etc]). Those with history of autoimmune or inflammatory disorders who are currently tolerating durvalumab may be eligible to participate with approval from the PI. The following are also exceptions to this criterion:

1. Vitiligo or alopecia

2. Hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement

3. Chronic skin condition not requiring systemic therapy

4. Celiac disease controlled by diet alone

11. History of primary immunodeficiency

12. History of organ transplant requiring therapeutic immunosuppression

13. History of hypersensitivity to carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel that is likely to prevent re-administration of these agents

14. Active infection including but not limited to:

• Grade 3 or higher clinically significant infection
• Active known Hepatitis B [known positive results for HBV surface antigen (HBsAg) within 2 months prior to enrollment]. EXCEPTION: Subjects with a past or resolved HBV infection, defined as the presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg are eligible
• Active known Hepatitis C (HCV). EXCEPTION: Subjects positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA
• Active known tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
• Active known HIV infection

15. Receipt of live attenuated vaccine within 30 days prior to the first dose of concurrent chemotherapy and durvalumab. Note: Subjects, if enrolled, should not receive live vaccine through 30 days after the last dose of chemotherapy concurrent with durvalumab.

16. Uncontrolled intercurrent illness, including but not limited to:

• Ongoing or active infection
• Symptomatic congestive heart failure
• Uncontrolled hypertension
• Unstable angina pectoris
• Cardiac arrhythmia
• Interstitial lung disease
• Serious chronic gastrointestinal conditions associated with diarrhea
• Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the subject to give written informed consent.

17. Female subjects who are pregnant or breast feeding; or subjects of reproductive potential of any gender who are not employing or who do not agree to employ an effective method of birth control prior to trial enrollment.ollment.

Exclusion Criteria

Involvement in the planning and/or conduct of the study

2. Previous enrollment or randomization in the present study

3. Received Investigational product as part of another clinical study

4. Mixed small cell and non small cell lung cancer histology

5. History of another primary malignancy and currently undergoing active treatment.

Exception: May participate if receiving adjuvant endocrine therapy for breast or prostate cancer.

6. Current or prior use of immunosuppressive medication within 14 days before enrollment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Maximilian Diehn

OTHER

Sponsor Role: lead

Responsible Party

Maximilian Diehn

Vice Chair of Research, Division Chief of Radiation and Cancer Biology

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Maximilian Diehn, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford Universiy

Locations

Stanford University

Stanford, California, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Rene Bonilla

Role: CONTACT

rbonilla@stanford.edu

650-498-7703

Facility Contacts

Rene NH Bonilla

Role: primary

rbonilla@stanford.edu

650-498-7703

Other Identifiers

LUN0114

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2021-09500

Identifier Type: OTHER

Identifier Source: secondary_id

IRB-54807

Identifier Type: -

Identifier Source: org_study_id